A Phase I Trial of CD19 Targeted ICAR19 T Cells in Patients With CD19+ Leukemia and Lymphoma.

Trial Profile

A Phase I Trial of CD19 Targeted ICAR19 T Cells in Patients With CD19+ Leukemia and Lymphoma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications B cell lymphoma; B-cell leukaemia
  • Focus Adverse reactions
  • Sponsors Immune Cell Therapy
  • Most Recent Events

    • 04 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top